首页> 外文期刊>Nuclear Medicine Review >Clinical significance of metabolic superscan in patients with hyperthyroidism
【24h】

Clinical significance of metabolic superscan in patients with hyperthyroidism

机译:甲状腺功能亢进患者代谢超扫描的临床意义

获取原文
       

摘要

BACKGROUND: Hyperthyroid patients commonly complain of generalized bony aches, which are frequently overlooked due to the more prominent symptoms of cardiovascular and nervous disturbances. Hyperthyroid patients are expected to have abnormal bone metabolism as part of the generalized hypermetabolic status. The aim of this study is to verify the presence of metabolic bone superscan in association with the hypermetabolic stats in various groups of hyperthyroidism. Secondly, to correlate these superscan features with the various laboratory results in hyperthyroid patients. MATERIAL AND METHODS: Forty-five hyperthyroid patients confirmed by clinical and laboratory results were enrolled in this work. In all patients, a 99m Tc-pertechnetate thyroid uptake scan was acquired. On a different day, total body bone scan was acquired three hours post IV injection of 555-925 MBq of 99m Tc-MDP. Serum FT3, FT4, TSH, Ca++, alkaline phosphatase (AP) and parathyroid hormone (PTH) were monitored in all patients as markers of thyroid and bone metabolism. Ten cases with no thyroid diseases were included as a control group. Patients with thyroiditis or long history of antithyroid drugs for more than one year were excluded from the study. RESULTS: The patients were subdivided into three groups: Graves′ disease (GD) (n = 30), toxic nodular goiter (TNG) (n = 10) and autonomous toxic adenoma (AT) (n = 5). The TSH for the whole group was significantly suppressed compared to the control group with higher suppression in the Graves′ disease group than in the TNG or AT groups. 99m Tc-pertechnetate uptake values in the Graves′ disease group were significantly higher than the TNG and AT groups (p 0.05). CONCLUSIONS: Disturbances in bone metabolism are more prevalent in Graves′ disease than in other types of hyperthyroidism. The addition of the bone scan to the diagnostic work up of patients with Graves′ disease is a sensitive indicator for metabolic bone changes and could help in the future management and follow up for this group of patients.
机译:背景:甲状腺功能亢进患者通常抱怨全身性骨痛,由于心血管和神经障碍的症状更加突出,因此经常被忽视。甲状腺功能亢进症患者预期具有异常的骨骼代谢,这是广义代谢亢进状态的一部分。这项研究的目的是验证各种甲亢患者中代谢骨超扫描与代谢异常相关。其次,将这些超级扫描特征与甲状腺功能亢进患者的各种实验室结果相关联。材料与方法:经临床和实验室结果证实的甲状腺功能亢进患者45例。在所有患者中,均进行了99m Tc-高net酸甲状腺摄取扫描。在另一天,静脉注射99m Tc-MDP 555-925 MBq后三小时,进行了全身骨扫描。监测所有患者的血清FT3,FT4,TSH,Ca ++,碱性磷酸酶(AP)和甲状旁腺激素(PTH),作为甲状腺和骨代谢的标志物。十例无甲状腺疾病的病例作为对照组。排除患有甲状腺炎或抗甲状腺药物病史超过一年的患者。结果:患者分为三组:格雷夫斯病(GD)(n = 30),中毒性结节性甲状腺肿(TNG)(n = 10)和自主毒性中毒腺瘤(AT)(n = 5)。与对照组相比,整个组的TSH受到显着抑制,在Graves病组中的抑制作用高于TNG或AT组。 Graves病组的99m Tc高tech酸盐摄取值显着高于TNG和AT组(p 0.05)。结论:在格雷夫斯病中,骨代谢紊乱比其他类型的甲状腺功能亢进更为普遍。在Graves病患者的诊断工作中增加骨骼扫描是代谢性骨改变的敏感指标,并且可能有助于该组患者的未来治疗和随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号